As part of the new process for creating cancer screening guidelines, the ACS Board of Directors appointed a Cancer Screening Guideline Development Group (GDG) to create all ACS cancer screening guidelines. The ACS GDG is consists of 11 generalist clinicians and population health care professionals, and 1 patient advocate. To avoid professional conflicts of interest in creating guidelines, the GDG considers content specific input and the opinions of expert clinical specialists, but is responsible for supervising the review of the evidence and transforming the evidence into writing the guidelines. Current members of the Guidelines Development Group are listed below.
Richard Wender, MD, Chair, ACS Guideline Development Group
Dr. Richard Wender is Alumni Professor and Chair of the Department of Family and Community Medicine at Thomas Jefferson University in Philadelphia. In addition to being a family doctor, Dr. Wender’s major areas of work are cancer prevention, screening and management of chronic illness. He has been a volunteer leader at multiple levels of the American Cancer Society, culminating in his election as national President from 2006-07, becoming the first primary care clinician to serve as President in the 93 year history of ACS. In December 2011, Dr. Wender was appointed Chair of the newly constituted American Cancer Society Cancer Screening Guidelines Panel. He also serves as Chair of the National Colorectal Roundtable, the CDC-ACS funded organization that advocated for eliminating colorectal cancer as a major public health problem.
Elizabeth T.H. Fontham, DrPH, MPH, Co-chair, ACS Guideline Development Group
Elizabeth T.H. Fontham, DrPH, MPH, Co-chair, ACS Guideline Development Group
Dr. Elizabeth (Terry) Fontham is Founding Dean of Louisiana State University Health Sciences Center School of Public Health (LSUHSC SPH) and Professor of Epidemiology. She also holds a joint appointment in the LSUHSC School of Medicine Department of Pathology. Dr. Fontham’s area of expertise is cancer epidemiology, with interest in tobacco and nutrition-related cancers and gastric cancer premalignant lesions. She has authored more than 170 publications in peer-reviewed scientific journals, book chapters, and monographs. Her current research includes innovative approaches to cervical cancer screening and long-term health effects related to exposures as a result of the Gulf of Mexico Oil Spill.
Tim Byers, MD, MPH
Dr. Byers is a professor at the University of Colorado and the Associate Dean for Public Health Practice at the Colorado School of Public Health. He also serves as Associate Director for Cancer Prevention and Control at the University of Colorado Comprehensive Cancer Center. He is a member of the Board of Directors of the American Cancer Society, and now serves as the National Vice President. Dr. Byers interest is in early detection, diet, and nutrition in the prevention of cancer, and in the application of disease prevention in community settings. He has authored over 340 papers scientific publications. His current research includes epidemiologic and clinical studies of nutrients as protective factors in colon, breast, and lung cancer, studies of cancer treatment decision-making by patients and physicians, studies of cancer genetics, and studies and programs to promote the early detection of lung and colorectal cancer.
Timothy R. Church, PhD
Dr. Timothy R. Church is a tenured professor at the University of Minnesota School of Public Health. His research interests is in chronic disease screening and prevention, and work including the Minnesota Colon Cancer Control Study, the Prostate Lung Colon and Ovarian Cancer Screening Trial, the National Colonoscopy Screening Trial, the Lung Screening Study, the National Lung Screening Trial, the Minnesota-Wisconsin Men’s Health Study, and the Colon Cancer Family Registry, as well as numerous studies on HIV/AIDS, cardiac arrhythmias, and occupational violence and injury. He has over 130 research publications and sits on national and international advisory boards, including the National Lung Screening Trial Executive Committee, and the PROSPR Consulting Committee.
Ruth Etzioni, PhD
Dr. Ruth Etzioni’s work focuses on statistical and computer modeling for policy development. A critical component of this work is the estimation of disease natural history and progression which then forms a substrate for modeling comparative- and cost-effectiveness of alternative interventions. Dr. Etzioni’s models of disease have been used to estimate the lifetime probabilities of prostate cancer and its outcomes, the extent of associated overdiagnosis, and quantify the roles of screening and changes in receipt of initial therapies in mortality declines. She serves on three national panels on prostate cancer early detection. Her work on prostate cancer modeling is done as part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) consortium, for which she serves on the steering committee and is the Principal Investigator on the Prostate Cancer Coordinating Center.
Christopher Flowers, MD
Dr. Flowers currently serves an Associate Professor of Hematology and Oncology at Winship Cancer Institute at Emory University School of Medicine and is Director of the Emory Lymphoma Program. Dr. Flowers is a widely published author of more than 85 papers in peer-reviewed scientific journals. His current research span three areas: 1) clinical trials and translational research in non-Hodgkin Lymphomas, 2) oncology informatics projects developing an information infrastructure to support pharmacogenomics and outcomes research, and 3) medical decision analyses and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients.
Samuel J. LaMonte, MD
Dr. Samuel LaMonte is a retired physician and retired United States Air Force flight surgeon. He is a longstanding volunteer with the ACS since 1976, and has served as President of the Florida Division and on the ACS Board of Directors. He also serves on the Survivorship Steering Committee for the Centers for Disease Control and Prevention grant. He received the National Volunteer of the Year Award in 2011. He has also been honored with the St. George Medal from ACS, and is a member of the Past Volunteer Leaders of the American Cancer Society. As a cancer survivor, Dr. LaMonte maintains a keen interest in cancer education, survivorship issues, cancer screening, and patient advocacy.
James Michaelson, PhD
Dr. James Michaelson is an Associate Professor of Pathology in the Departments of Pathology and Surgery at the Massachusetts General Hospital, and the Department of Pathology, Harvard Medical School, Boston, MA. He received his Doctorate in Biology at Cornell University and Postdoctoral Training in Immunogenetics at the Memorial Sloan-Kettering Institute. His research concerns the collection of data, and the development of improved mathematical methods for predicting cancer outcome, the analysis of cancer screening, and the use of modern computer speech and telephony to design systems that improve patient compliance.
Kevin Oeffinger, MD
Dr. Oeffinger is a family physician, a Full Member in the Departments of Medicine and Pediatrics at Memorial Sloan-Kettering Cancer Center (MSKCC), and Director of the MSKCC Adult Long-Term Follow-Up (LTFU) Program. Dr. Oeffinger is an NIH-funded investigator studying cardiovascular late effects of cancer therapy and breast cancer following chest radiotherapy. He serves in a number of leadership roles for national organizations including: Chair, American Society of Clinical Oncology (ASCO) Cancer Survivorship Committee; Chair, Leukemia & Lymphoma Society Quality of Life Research Initiative; and Member of the American Cancer Society Board of Directors.
Ya-Chen Tina Shih, PhD
Dr. Shih is currently Associate Professor at Department of Medicine, University of Chicago. She is also the Program Director in the Economics of Cancer, and Affiliated Faculty at the Center for Health and the Social Sciences. Dr. Shih’s area of expertise is in health economics and health services research and with particular interest in the economics of cancer. She has over 80 peer-reviewed publications and has co-authored 4 book chapters. Her current research includes the impact of technology diffusion in costs and outcomes of cancer, evaluating the cost-effectiveness of various policy, behavioral, and medical interventions for cancer, and methodological issues in health services research.
Louise C. Walter, MD
Dr. Louise Walter is a Professor of Medicine and Interim Chief of the Division of Geriatrics at the University of California, San Francisco (UCSF). She is a geriatrician at the San Francisco VA and Director of their Health Services Research Enhancement Award Program. Dr. Walter’s research interests include prognostication and cancer screening in older persons with particular interest in studying the importance of life expectancy, rather than age, in determining real-world risks and benefits of cancer screening in older adults. Dr. Walter has more than 50 peer-reviewed publications and has co-authored several book chapters. Her current work focuses on downstream outcomes of prostate-specific antigen screening in older men and the juxtaposition of lag-time-to-benefit of preventive services and life expectancy to help individualize screening decisions.
Andrew Wolf, MD
Dr. Andrew Wolf is a General Internist physician and Associate Professor of Medicine at the University of Virginia (UVA) School of Medicine in Charlottesville, Virginia. He serves as Associate Program Director for the UVA Internal Medicine Residency Program and directs its Primary Care Track. His areas of expertise are cancer screening and medical education, with research interest in enhancing patient involvement in cancer screening decisions. For his educational accomplishments, he has won 16 teaching awards and has achieved the “Best Doctors in America” distinction for four of the past eight years. Dr. Wolf has been involved with guideline development with the ACS since 2001, and chaired the ACS Prostate Cancer Advisory Committee that developed the 2010 prostate cancer screening guideline.